Biosceptre

Biosceptre is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, and Sydney, Australia, that develops targeted antibody and CAR T-cell therapies for solid tumors. The organization focuses on treatments and diagnostics targeting nf-P2X7, a specific receptor found exclusively on cancer cells, to induce programmed cell death while minimizing side effects in healthy tissue. Operating with fewer than 50 employees, the biotechnology firm has raised over $40 million AUD in early private funding rounds to advance its pipeline. Biosceptre has completed Phase I clinical trials for its systemic and topical antibody therapies and presented preclinical data at the American Society of Clinical Oncology. The company is backed by investors including Tuspark and features scientific advisors such as Nobel Laureate Sir Gregory Winter and Professor Terrence Rabbitts. Biosceptre was founded in 2001 by Professor Julian Barden.